Nucleic acid Construct
A promoter for high level and sustained expression is provided which can be used for gene expression of chosen sequences in general. In particular, a nucleic acid construct comprising a hCEF1 promoter operably linked to a sequence for expression is provided, where the hCEF1 promoter comprises: (i) a human CMV enhancer operably linked to a human EFI a promoter; (ii) a functional fragment of (i); or (ii) a functional variant of (i) or (ii).
1. A nucleic acid construct comprising a hCEFI promoter operably linked to a sequence for expression, wherein the hCEFI promoter consists of nucleotides 7 to 538 of SEQ ID NO:1, wherein the hCEFI promoter does not comprise any CpG dinucleotides, and wherein a non-promoter sequence of the construct comprises a CpG dinucleotide.
2. The construct of claim 1 , wherein the construct is a plasmid construct.
3. The construct of claim 1 , wherein the construct comprises a kanamycin resistance marker.
4. The construct of claim 1 , wherein the sequence for expression encodes a therapeutic polypeptide.
5. A pharmaceutical composition comprising the construct of claim 1 and a pharmaceutically acceptable carrier or excipient.
6. The construct of claim 1 , wherein the sequence for expression operably linked to the hCEFI does not comprise any CpG dinucleotides.
7. The construct of claim 4 , wherein the encoded therapeutic polypeptide comprises a CFTR polypeptide, wherein the sequence for expression comprises: (i) the contiguous nucleotides 738 to 5180 of SEQ ID No: 2; (ii) the contiguous nucleotides 738 to 5180 of SEQ ID No: 2 in which nucleotide 2595 is C and/or nucleotide 3234 and 3236 are T and C respectively, (iii) a sequence having at least 70% sequence identity to the sequence of (i) or (ii); or (iv) a complement of the sequence of (i), (ii), or (iii).